Acitretin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Acitretin.svg | |
| Acitretin
| |
| Systematic (IUPAC) name | |
| 9-(4-methoxy-2,3, 6-trimethyl-phenyl)- 3,7-dimethyl-nona-2,4,6,8- tetraenoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | D05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H26O3 |
| Mol. mass | 326.429 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Acitretin (trade name Soriatane®) is a second generation retinoid. It is taken orally, and is typically used for psoriasis.
It is a metabolite of etretinate, which was used prior to the introduction of acitretin. Etretinate was discontinued because it had a narrow therapeutic index as well as a long elimination half-life (t1/2=120 days), making dosing difficult. In contrast, acitretin's half-life is approximately 2 days.
Women must avoid becoming pregnant for at least 3 years after discontinuing acitretin. In comparison, etretinate was not recommended at all for women who planned to become pregnant.
Antipsoriatics (D05) | |
|---|---|
| Topical: tars | Tar |
| Topical: antracens | Dithranol |
| Topical: psoralens | Trioxysalen - Methoxsalen |
| Topical: other | Fumaric acid - Calcipotriol - Calcitriol - Tacalcitol - Tazarotene |
| Systemic: psoralens | Trioxysalen - Methoxsalen - Bergapten |
| Systemic: retinoids | Etretinate - Acitretin |
